TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: The Effect of Tourniquet Use During Total Knee Arthroplasty Surgery on the Postoperative Loss of Quadricepsforce
Brief Summary: The purpose for this study is to investigate the quadriceps (thigh) function preoperatively and 48 hours postoperatively during knee arthroplasty (total replacement of the knee joint) in a randomised study with or without the use of a Tourniquet (cuff around the thigh during surgery) (100 mm Hg \> systolic blood pressure).


Options:
A: isometric quadriceps-force measured (pre operatively and 48 hrs post op)
B: Biochemical Data (During operation 60 min Ischemia/Shame-Ischemia Time)
C: Isometric Quadriceps Strength (2 weeks)
D: Length of hospital stay (participants will be followed for the duration of hospital stay, an expected average of 3 days").)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Trial Evaluating the Number of Passes Required for Diagnostic Cell Block During Endoscopic Ultrasound-Fine Needle Aspiration of Solid Pancreatic Mass Lesions
Brief Summary: This study will test the amount of tissue, called "cell block", obtained from your pancreas. Patients who are asked to participate in this study have a growth (mass) in the pancreas that needs a biopsy so a diagnosis can be made. Although we usually perform 2 to 4 passes (number of times the doctor biopsies the mass), at this time we do not know the ideal number of passes needed to obtain adequate amount of tissue for making a diagnosis. The purpose of this study is to compare the amount of tissue obtained with 2 passes versus 4 passes.


Options:
A: number of passes (up to 12 months)
B: Diagnostic performance of the Cellvizio nCLE system in the characterization of pancreatic cysts (Within 6 months after the end of Follow-up period); Descriptive criteria in nCLE sequences for the characterization of pancreatic masses and lymph nodes (Within one year after the end of the follow-up period)
C: Compare the Median Number of Passes Required to Establish a Diagnosis (6 months)
D: Compare the degree of cytologic quality in specimen obtained by EUS-FNA with or without suction, pushing the stylet or injecting air. (within 6 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.
Brief Summary: Pain, in neoplastic disease, is a symptom with severe negative impact on the quality of life of patients and a high incidence, with values around 70-90% in advanced and metastatic stages. Than 20 years the main reference for the pharmacological treatment of cancer pain are the guidelines produced by the World Health Organization (WHO). This document shows that the use of opioid drugs is the mainstay of treatment, with particular reference to opioids "major" (3 rd step of the analgesic ladder). The 4 opioids more most commonly prescribed in Italy (oral morphine and oxycodone, fentanyl and buprenorphine transdermal), based on the data currently available, have an analgesic effect would partly overlap but with different percentages of non-responders (NR), a different need to increase the dose over time to maintain adequate analgesia, a different action to the switch to another molecule for ineffectiveness analgesic. The observations described suggest that opioids, although they belong to the same family drug may not be fully comparable with regard to the clinical effects products. Important differences are known on the pharmacokinetic and pharmacodynamic and, more recently, also in terms of pharmacogenomics. This is a comparative study of analgesic strategies based on the use of the 4 mentioned opioids, going to look for possible differences in terms of analgesic efficacy, changes in dose over time, use of switch or permanent abandonment of treatment, parallel to the contour of the side effects. The associated sub-project will link the structure gene of patients and clinical results have emerged.


Options:
A: Change in the Mean Pain Score(NRS) From Baseline(Day 0) to Day 5. (5 days)
B: Change From Baseline to the Last 3 Days of Study Drug Administration (Last Observation Carried Forward) in the Score for Average Pain Intensity on an 11-point Numerical Rating Scale (Baseline, Last 3 Days of Study Drug Administration (4 weeks))
C: Achievement of analgesia (decrease of at least 1/3 of pain intensity) assessed by NRS scale (within 15 days)
D: Proportion of Non-Responder (NR) Participants (28 days)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.
Brief Summary: Pain, in neoplastic disease, is a symptom with severe negative impact on the quality of life of patients and a high incidence, with values around 70-90% in advanced and metastatic stages. Than 20 years the main reference for the pharmacological treatment of cancer pain are the guidelines produced by the World Health Organization (WHO). This document shows that the use of opioid drugs is the mainstay of treatment, with particular reference to opioids "major" (3 rd step of the analgesic ladder). The 4 opioids more most commonly prescribed in Italy (oral morphine and oxycodone, fentanyl and buprenorphine transdermal), based on the data currently available, have an analgesic effect would partly overlap but with different percentages of non-responders (NR), a different need to increase the dose over time to maintain adequate analgesia, a different action to the switch to another molecule for ineffectiveness analgesic. The observations described suggest that opioids, although they belong to the same family drug may not be fully comparable with regard to the clinical effects products. Important differences are known on the pharmacokinetic and pharmacodynamic and, more recently, also in terms of pharmacogenomics. This is a comparative study of analgesic strategies based on the use of the 4 mentioned opioids, going to look for possible differences in terms of analgesic efficacy, changes in dose over time, use of switch or permanent abandonment of treatment, parallel to the contour of the side effects. The associated sub-project will link the structure gene of patients and clinical results have emerged.


Options:
A: Proportion of Non-Responder (NR) Participants (28 days)
B: Achievement of analgesia (decrease of at least 1/3 of pain intensity) assessed by NRS scale (within 15 days)
C: Change From Baseline to the Last 3 Days of Study Drug Administration (Last Observation Carried Forward) in the Score for Average Pain Intensity on an 11-point Numerical Rating Scale (Baseline, Last 3 Days of Study Drug Administration (4 weeks))
D: Efficacy variable: Bowel Function Index (BFI) score. Amount of laxative medication use recorded at each assessment visit (4 weeks and a 6 month open label); Efficacy variable: Brief Pain Inventory Short-Form (BPI-SF) (Cleeland, 1991). Amount of analgesic rescue medication used (4 weeks and a 6 month open label)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients
Brief Summary: The third generation oral aromatase inhibitors (AIs) are increasingly being used in the management of estrogen receptor positive breast cancer. One of the issues related with administration of oral AIs is their side effects, particularly on the musculoskeletal system. Although the prevalence and importance of arthralgia and myalgia occurring in BC patients receiving adjuvant AIs are evident, the mechanisms clearly explaining these invalidating symptoms are unknown.

In this project, we aim to unravel the interaction between vitamin D and musculoskeletal adverse events experienced by AI users. We will also evaluate how vitamin D supplementation affects AI-induced musculoskeletal symptoms in breast cancer patients, by means of a randomized placebo-controlled double blind clinical trial. We will assess changes in the musculoskeletal system by using magnetic resonance imaging of joints, hand grip strength and also monitor serum IGF-I and estrogen levels together with bone resorption and formation markers.


Options:
A: Change from baseline in musculoskeletal pain and 250HD levels (3 monthly during one year)
B: To evaluate patient willingness to use STAR (Symptom Tracking and Reporting for Patients), an Internet-based system for cancer patients to self-report common toxicity symptoms, performance status, and quality of life. (conclusion of study); To evaluate the impact of STAR on clinical outcomes (2 years)
C: Arthralgia incidence, defined as proportion of the baseline population (those who have taken ≥ 9 doses of aromatase inhibitor [AI]) in which new or worsening joint pain or stiffness is observed at 1, 3, and 12 months after beginning AI therapy (12 months); Time to onset of arthralgia (continuous variable in weeks) among baseline population (12 months); Arthralgia point prevalence, defined as proportion of the baseline population with a score of ≥ 2 on any one dimension of the outcome measure at 1, 3, and 12 months after beginning AI therapy (12 months)
D: Change in Musculoskeletal Symptom Sub-scale on the Breast Cancer Prevention Trial Symptom Scale (baseline to 6 months); Change in Hand Grip Strength (baseline to 6 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants
Brief Summary: The purpose of this study is to determine whether a 14 week intervention is successful in improving outcomes for women with gestational diabetes mellitus and their infants.


Options:
A: Food intake (1 month)
B: fasting blood glucose (Baseline to 10 months postpartum); weight (body mass index) (Baseline to 10 months postpartum)
C: body mass index (three years)
D: Vegetable Flavor Acceptance [Infants' Intake] (6- to 10-month-old weaned infants (3 separate test days )); Taste Liking Ratings of Vegetable Flavors [Mothers]. (Monthly, 0.5 to 4.5 months); Vegetable Flavor Acceptance (Infants' Rate of Feeding) (6- to 10-month-old weaned infants (3 separate test days))

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants
Brief Summary: The purpose of this study is to determine whether a 14 week intervention is successful in improving outcomes for women with gestational diabetes mellitus and their infants.


Options:
A: Provision of flesh-food or vitamin A-rich food (Change from baseline to 5 months)
B: Maintenance of a Child's Body Mass Index as a result of the intervention (up to two years)
C: N/A
D: fasting blood glucose (Baseline to 10 months postpartum); weight (body mass index) (Baseline to 10 months postpartum)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants
Brief Summary: The purpose of this study is to determine whether a 14 week intervention is successful in improving outcomes for women with gestational diabetes mellitus and their infants.


Options:
A: fasting blood glucose (Baseline to 10 months postpartum); weight (body mass index) (Baseline to 10 months postpartum)
B: Glycemic control (one year)
C: Gestational diabetes diagnosis assessed through glucose tolerance test. (28 weeks gestational age)
D: Serum fasting glucose values. (Fasting glucose will be measured at recruitment (24 weeks of gestation) and at the end of follow-up (38 weeks of gestation))

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants
Brief Summary: The purpose of this study is to determine whether a 14 week intervention is successful in improving outcomes for women with gestational diabetes mellitus and their infants.


Options:
A: Change in grams of fruit and vegetables consumed (Baseline (prior to randomization allocation of installation of salad bars), Time 2 (6 weeks after randomization), and Time 3 (10 weeks after randomization))
B: fasting blood glucose (Baseline to 10 months postpartum); weight (body mass index) (Baseline to 10 months postpartum)
C: Body Mass Index score(BMI sds) at the age 6 years to monitor the effectiveness of the intervention (5 years)
D: 1 Year change in insulin resistance via HOMA-IR (Change during first year); 2 year change in insulin resistance via HOMA-IR (Change during 2 years)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants
Brief Summary: The purpose of this study is to determine whether a 14 week intervention is successful in improving outcomes for women with gestational diabetes mellitus and their infants.


Options:
A: Stunting in Children at 18 mo (18 months of age)
B: Absolute change in mean accelerometry counts over 6 days (baseline, end of intervention, six months after end of intervention)
C: Body mass index (2005, 2006, 2007, 2008); nutrition behavior (2005, 2006, 2007, 2008); physical activity (2005, 2006, 2007, 2008)
D: fasting blood glucose (Baseline to 10 months postpartum); weight (body mass index) (Baseline to 10 months postpartum)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants
Brief Summary: The purpose of this study is to determine whether a 14 week intervention is successful in improving outcomes for women with gestational diabetes mellitus and their infants.


Options:
A: fasting blood glucose (Baseline to 10 months postpartum); weight (body mass index) (Baseline to 10 months postpartum)
B: Postpartum weight retention (no more than 1.5 years)
C: Number of Participants With Composite Neonatal Morbidity (Delivery through discharge of infant from hospital up to 120 days); Number of Children at the 5-10 Year Followup With BMI ≥ 95th Percentile for Age and Sex (Age 5-10 years)
D: The Rate of Macrosomia. (At the time of birth.)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants
Brief Summary: The purpose of this study is to determine whether a 14 week intervention is successful in improving outcomes for women with gestational diabetes mellitus and their infants.


Options:
A: Exclusive Breastfeeding Rate (3 months postpartum)
B: BMI change from baseline to 12 months post-intervention (24 months postpartum) will be assessed via self-report and validated by in-person weight measurement. The proportion of women who lose 10% of baseline BMI
C: Postpartum weight loss (12 months after delivery)
D: fasting blood glucose (Baseline to 10 months postpartum); weight (body mass index) (Baseline to 10 months postpartum)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants
Brief Summary: The purpose of this study is to determine whether a 14 week intervention is successful in improving outcomes for women with gestational diabetes mellitus and their infants.


Options:
A: Physical Activity Level (The intervention spans a period of 6 months. Outcomes are measured before and after intervention.); Physical Literacy (The intervention spans a period of 6 months. Outcomes are measured before and after intervention.); Dietary Intake (The intervention spans a period of 6 months. Outcomes are measured before and after intervention.)
B: fasting blood glucose (Baseline to 10 months postpartum); weight (body mass index) (Baseline to 10 months postpartum)
C: Child anthropometry (Baseline. Up to 12 months. Up to 24 months.); Child food intake (Baseline. Up to 12 months. Up to 24 months.); Child health (Baseline. Up to 12 months. Up to 24 months.); Distribution of food intake within the household (Baseline. Up to 12 months. Up to 24 months.); Household food security (Baseline. Up to 12 months. Up to 24 months.); Maternal nutrition knowledge (Baseline. Up to 12 months. Up to 24 months.)
D: Body Mass Index score(BMI sds) at the age 6 years to monitor the effectiveness of the intervention (5 years)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Sustainable Financial Incentives To Improve Prescription Practices For Malaria
Brief Summary: This project aims to test an innovative, sustainable financial incentive designed to reduce the number of non-malarial fevers that are treated inappropriately with antimalarial drugs.


Options:
A: Receipt of two or more home visits from an FLW in the final trimester of pregnancy and delivery at a facility (versus home birth), using maternal survey response (2 year follow-up); Receipt of any postnatal home visits from an FLW (in the first 24 hours at home after delivery and in first month following delivery), using maternal survey response (2 year follow-up); Any complementary feeding of solid or semisolid food for infants aged 6-11 months, using maternal survey response (2 year follow-up); Immunizations (2 year follow-up); Receipt of iron-folic acid tablets by month 4 and consumption of at least 90 tablets, using maternal survey response (2 year follow-up); Clean Cord Care (2 year follow-up); Kangaroo Mother Care (skin to skin care) (2 year follow-up); Delayed Bath (2 year follow-up); Initiation of Breastfeeding (2 year follow-up); Nothing applied to cord or umbilicus (2 year follow-up); Health worker placed child unclothed on mother's chest/abdomen in skin-to-skin contact (2 year follow-up); First bath delayed by two or more days (2 year follow-up); Breastfed child within one hour of birth (2 year follow-up)
B: Number of Participants Who Present Children for HIV Testing (2 months); Number of Days Participants Take to Bring Children for HIV Testing (2 months)
C: Change in recovery rate of acute malnutrition in children below five years old over two years (26 months from baseline; endline survey in December 2016); Difference in prevalence of acute malnutrition among children aged 6-23 months between Dec 2014 and Dec 2016 (Two years from baseline; endline survey in December 2016)
D: Proportion of children under 5 years of age who are treated with antimalarials following a negative malaria test (At one year post-intervention)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Study of Surgical Methods for Keratoconus
Brief Summary: The purpose of this study is to determine which surgical method makes less corneal haze


Options:
A: Best corrected visual acuity (at six months after surgery)
B: Mean Change From Baseline in Maximum Keratometry (Kmax) (baseline,12 months)
C: Mean Change From Baseline in Maximum Keratometry (Kmax) (baseline,12 months)
D: Change in keratometry (3 Months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Study of Surgical Methods for Keratoconus
Brief Summary: The purpose of this study is to determine which surgical method makes less corneal haze


Options:
A: evaluation of depth of demarcation line (1 month postoperative)
B: Best corrected visual acuity (at six months after surgery)
C: Change in Maximum Keratometry From Baseline to 6 Months After Treatment (6 months)
D: Visual acuity (1 year); Keratometry measurements (1 year)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Controlled Trial of Stress Reduction in the Secondary Prevention of Coronary Heart Disease in African Americans
Brief Summary: The overall hypothesis of this study is that a cardiac rehabilitation program with meditation will be more effective than cardiac rehabilitation alone in improving blood flow through the diseased coronary arteries in African Americans. For this purpose, 56 African American men and women with coronary heart disease will be randomly assigned either to standard cardiac rehabilitation plus the Transcendental Meditation program or to standard cardiac rehabilitation alone. The treatment period will be 12 weeks in length.


Options:
A: Low-density lipoprotein (LDL)cholesterol (Baseline and 12 months); Blood pressure (baseline and 12 months); Body Mass Index (baseline and 12 months); Psychological Well-Being (Baseline and 12 months)
B: coronary blood flow as measured by PET (12 weeks)
C: In-clinic and ambulatory blood pressure (Measured at Month 4)
D: Point prevalence abstinence at 6 months (6 months after beginning treatment)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Integrated Collaborative Care for Substance Use Disorders
Brief Summary: Primary care settings (PCS) are a missed opportunity for delivering evidence-based treatments for opiate and alcohol-use disorders (OAUD). The investigators propose to evaluate the costs and effectiveness of two strategies to increase the delivery of OAUD treatments in PCS, integrated collaborative care (ICC) and education and resources (E\&R). The investigators hypothesize that ICC will be more effective than E\&R in promoting A. Implementation outcomes B. Service system outcomes and C. Patient outcomes.

Results from our study will help providers choose between two different strategies and advance the field of implementation research.


Options:
A: Proportion of participants with a PrEP prescription at baseline who initiate PrEP (6 months post enrollment); Proportion of participants with a PrEP prescription at baseline who attend at least one follow-up visit and have at least one documented PrEP prescription refill during each 3-month interval (6 months post enrollment); Percentage of participants with a PrEP prescription at baseline who adhere to their PrEP regimen (6 months post enrollment)
B: Framingham cardiovascular disease risk (12 months)
C: Amount of calcium supplement ingested (8 weeks after ANC consultation, during which recruitment into the study occurred)
D: unmet need (past 6 months); abstinent from alcohol and opioid use, past 30 days (past 30 days); negative consequences related to substance use (past 3 months); Functioning (past 4 weeks); Engagement (30 days of initiation); initiation (Within 14 days of index visit); heavy alcohol use (6 months)

Answer: D